Does switching from oral extended-release methylphenidate to the methylphenidate transdermal system affect health-related quality-of-life and medication satisfaction for children with attention-deficit/hyperactivity disorder?

Oscar G Bukstein, L Eugene Arnold, Jeanne M Landgraf, Paul Hodgkins, Oscar G Bukstein, L Eugene Arnold, Jeanne M Landgraf, Paul Hodgkins

Abstract

Background: To evaluate health-related quality of life (HRQL) and medication satisfaction after switching from a stable dose of oral extended-release methylphenidate (ER-MPH) to methylphenidate transdermal system (MTS) via a dose-transition schedule in children with attention-deficit/hyperactivity disorder (ADHD).

Methods: In a 4-week, multisite, open-label study, 171 children (164 in the intent-to-treat [ITT] population) aged 6-12 years diagnosed with ADHD abruptly switched from a stable dose of oral ER-MPH to MTS nominal dosages of 10, 15, 20, and 30 mg using a predefined dose-transition schedule. Subjects remained on the scheduled dose for the first week, after which the dose was then titrated to an optimal effect. The ADHD Impact Module-Children (AIM-C), a disease-specific validated HRQL survey instrument measuring child and family impact, was used to assess the impact of ADHD symptoms on the lives of children and their families at baseline and study endpoint. Satisfaction with MTS use was assessed via a Medication Satisfaction Survey (MSS) at study endpoint. Both the AIM-C and MSS were completed by a caregiver (parent/legally authorized representative). Tolerability was monitored by spontaneous adverse event (AE) reporting.

Results: AIM-C child and family HRQL mean scores were above the median possible score at baseline and were further improved at endpoint across all MTS doses. Similar improvements were noted for behavior, missed doses, worry, and economic impact AIM-C item scores. Overall, 93.8% of caregivers indicated a high level of satisfaction with their child's use of the study medication. The majority of treatment-emergent AEs (> 98%) were mild to moderate in intensity, and the most commonly reported AEs included headache, decreased appetite, insomnia, and abdominal pain. Seven subjects discontinued the study due to intolerable AEs (n = 3) and application site reactions (n = 4).

Conclusion: This study demonstrates that MTS, when carefully titrated to optimal dose, may further improve child and family HRQL, as well as behavioral, medication worry, and economic impact item scores, as measured by the AIM-C in subjects switching to MTS from a stable dose of routinely prescribed oral ER-MPH after a short treatment period. Furthermore, following the abrupt conversion from oral ER-MPH to MTS, the majority of caregivers reported being highly satisfied with MTS as a treatment option for their children with ADHD.

Trial registration: NCT00151983.

Figures

Figure 1
Figure 1
MTS abrupt conversion study design. MTS = methylphenidate transdermal system; MPH = methylphenidate.
Figure 2
Figure 2
Subject disposition flow chart.

References

    1. Pliszka S. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007;46:894–921. doi: 10.1097/chi.0b013e318054e724.
    1. Arnold LE. Contemporary Diagnosis and Management of ADHD. Newton, PA: Handbooks in Health Care Co; 2004.
    1. American Academy of Pediatrics Committee on Quality Improvement, Subcommittee on Attention-Deficit/Hyperactivity Disorder. Clinical practice guideline: Diagnosis and evaluation of the child with attention-deficit/hyperactivity disorder. Pediatrics. 2000;105:1158–1170. doi: 10.1542/peds.105.5.1158.
    1. Barkley RA, Fischer M, Edelbrock CS, Smallish L. The adolescent outcome of hyperactive children diagnosed by research criteria: I. An 8-year prospective follow-up study. J Am Acad Child Adolesc Psychiatry. 1990;29:546–557. doi: 10.1097/00004583-199007000-00007.
    1. Biederman J, Faraone SV, Spencer T, Wilens T, Norman D, Lapey KA, Mick E, Lehman BK, Doyle A. Patterns of psychiatric comorbidity, cognition, and psychosocial functioning in adults with attention deficit hyperactivity disorder. Am J Psychiatry. 1993;150:1792–1798.
    1. Biederman J, Faraone SV, Spencer TJ, Mick E, Monuteaux MC, Aleardi M. Functional impairments in adults with self-reports of diagnosed ADHD: A controlled study of 1001 adults in the community. J Clin Psychiatry. 2006;67:524–540.
    1. Mannuzza S, Klein RG, Bonagura N, Malloy P, Giampino TL, Addalli KA. Hyperactive boys almost grown up. V. Replication of psychiatric status. Arch Gen Psychiatry. 1991;48:77–83.
    1. Spencer TJ, Biederman J, Mick E. Attention-deficit/hyperactivity disorder: Diagnosis, lifespan, comorbidities, and neurobiology. J Pediatr Psychol. 2007;32:631–642. doi: 10.1093/jpepsy/jsm005.
    1. Biederman J. Attention-deficit/hyperactivity disorder: A life-span perspective. J Clin Psychiatry. 1998;59(Suppl 7):4–16.
    1. Biederman J, Faraone S, Milberger S, Guite J, Mick E, Chen L, Mennin D, Marrs A, Ouellette C, Moore P, Spencer T, Norman D, Wilens T, Kraus I, Perrin J. A prospective 4-year follow-up study of attention-deficit hyperactivity and related disorders. Arch Gen Psychiatry. 1996;53:437–446.
    1. Biederman J, Newcorn J, Sprich S. Comorbidity of attention deficit hyperactivity disorder with conduct, depressive, anxiety, and other disorders. Am J Psychiatry. 1991;148:564–577.
    1. Minde K, Lewin D, Weiss G, Lavigueur H, Douglas V, Sykes E. The hyperactive child in elementary school: A 5 year, controlled, follow-up. Except Child. 1971;38:215–221.
    1. Adesman AR. The diagnosis and management of attention-deficit/hyperactivity disorder in pediatric patients: Primary care companion. J Clin Psychiatry. 2001;3:66–77.
    1. Johnston C, Mash EJ. Families of children with attention-deficit/hyperactivity disorder: Review and recommendations for future research. Clin Child Fam Psychol Rev. 2001;4:183–207. doi: 10.1023/A:1017592030434.
    1. Swensen AR, Birnbaum HG, Secnik K, Marynchenko M, Greenberg P, Claxton A. Attention-deficit/hyperactivity disorder: Increased costs for patients and their families. J Am Acad Child Adolesc Psychiatry. 2003;42:1415–1423. doi: 10.1097/00004583-200312000-00008.
    1. Designating September 7th, 2004, as "National Attention Deficit Disorder Day.". S Res 370, 108th Cong 2nd Session. 2004.
    1. Greenhill LL, Halperin JM, Abikoff H. Stimulant medications. J Am Acad Child Adolesc Psychiatry. 1999;38:503–512. doi: 10.1097/00004583-199905000-00011.
    1. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD. Arch Gen Psychiatry. 1999;56:1073–1086. doi: 10.1001/archpsyc.56.12.1073.
    1. Wilens TE, Biederman J. The stimulants. Psychiatr Clin North Am. 1992;15:191–222.
    1. Robison LM, Sclar DA, Skaer TL, Galin RS. National trends in the prevalence of attention-deficit/hyperactivity disorder and the prescribing of methylphenidate among school-age children: 1990-1995. Clin Pediatr. 1999;38:209–217. doi: 10.1177/000992289903800402.
    1. Daytrana® [package insert] Wayne, PA: Shire US Inc.; 2008.
    1. Noven Pharmaceuticals Inc. DOT Matrix® Technology. Shire US Inc.; 2008. Accessed January 3, 2008.
    1. Heal DJ, Pierce DM. Methylphenidate and its isomers: Their role in the treatment of attention-deficit hyperactivity disorder using a transdermal delivery system. CNS Drugs. 2006;20:713–738. doi: 10.2165/00023210-200620090-00002.
    1. Wilens TE, Boellner SW, Lopez FA, Turnbow JM, Wigal SB, Childress AC, Abikoff HB, Manos MJ. Varying the wear time of the methylphenidate transdermal system in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2008;47:700–708. doi: 10.1097/CHI.0b013e31816bffdf.
    1. Pelham WE Jr, Manos MJ, Ezzell CE, Tresco KE, Gnagy EM, Hoffman MT, Onyango AN, Fabiano GA, Lopez-Williams A, Wymbs BT, Caserta D, Chronis AM, Burrows-Maclean L, Morse G. A dose-ranging study of a methylphenidate transdermal system in children with ADHD. J Am Acad Child Adolesc Psychiatry. 2005;44:522–529. doi: 10.1097/01.chi.0000157548.48960.95.
    1. Pelham WE, Burrows-Maclean L, Gnagy EM, Fabiano GA, Coles EK, Tresco KE, Chacko A, Wymbs BT, Wienke AL, Walker KS, Hoffman MT. Transdermal methylphenidate, behavioral, and combined treatment for children with ADHD. Exp Clin Psychopharmacol. 2005;13:111–126. doi: 10.1037/1064-1297.13.2.111.
    1. McGough JJ, Wigal SB, Abikoff H, Turnbow JM, Posner K, Moon E. A randomized, double-blind, placebo-controlled, laboratory classroom assessment of methylphenidate transdermal system in children with ADHD. J Atten Disord. 2006;9:476–485. doi: 10.1177/1087054705284089.
    1. Findling RL, Bukstein OG, Melmed RD, López FA, Sallee FR, Arnold LE, Pratt RD. A randomized, double-blind, placebo-controlled, parallel-group study of methylphenidate transdermal system in pediatric patients with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2008;69:149–159. doi: 10.4088/JCP.v69n0120.
    1. Wehmeier PM, Schacht A, Dittmann RW, Dopfner M. Global impression of perceived difficulties in children and adolescents with attention-deficit/hyperactivity disorder: Reliability and validity of a new instrument assessing perceived difficulties from a patient, parent and physician perspective over the day. Child Adolesc Psychiatry Ment Health. 2008;2:10. doi: 10.1186/1753-2000-2-10.
    1. Saylor K, Buermeyer C, Sutton V, Faries D, Khan S, Schuh K. The Life Participation Scale for Attention-Deficit/Hyperactivity Disorder-Child Version: Psychometric properties of an adaptive change instrument. J Child Adolesc Psychopharmacol. 2007;17:831–842. doi: 10.1089/cap.2007.0030.
    1. Varni JW, Burwinkle TM. The PedsQL as a patient-reported outcome in children and adolescents with attention-deficit/hyperactivity disorder: A population-based study. Health Qual Life Outcomes. 2006;4:26. doi: 10.1186/1477-7525-4-26.
    1. Rentz AM, Matza LS, Secnik K, Swensen A, Revicki DA. Psychometric validation of the child health questionnaire (CHQ) in a sample of children and adolescents with attention-deficit/hyperactivity disorder. Qual Life Res. 2005;14:719–734. doi: 10.1007/s11136-004-0832-9.
    1. Landgraf JM, Rich M, Rappaport L. Measuring quality of life in children with attention-deficit/hyperactivity disorder and their families: Development and evaluation of a new tool. Arch Pediatr Adolesc Med. 2002;156:384–391.
    1. Schmidt LJ, Garratt AM, Fitzpatrick R. Child/parent-assessed population health outcome measures: A structured review. Child Care Health Dev. 2002;28:227–237. doi: 10.1046/j.1365-2214.2002.00266.x.
    1. Eiser C, Morse R. A review of measures of quality of life for children with chronic illness. Arch Dis Child. 2001;84:205–211. doi: 10.1136/adc.84.3.205.
    1. Connolly MA, Johnson JA. Measuring quality of life in pediatric patients. Pharmacoeconomics. 1999;16:605–625. doi: 10.2165/00019053-199916060-00002.
    1. Landgraf J, Abetz L, Ware J. The CHQ User's Manual. Boston, MA: HealthActCHQ Inc.; 1999.
    1. Flapper BC, Schoemaker MM. Effects of methylphenidate on quality of life in children with both developmental coordination disorder and ADHD. Dev Med Child Neurol. 2008;50:294–299. doi: 10.1111/j.1469-8749.2008.02039.x.
    1. Bastiaens L. Both atomoxetine and stimulants improve quality of life in an ADHD population treated in a community clinic. Psychiatr Q. 2008;79:133–137. doi: 10.1007/s11126-008-9070-6.
    1. Wehmeier PM, Dittmann RW, Schacht A, Minarzyk A, Lehmann M, Sevecke K, Lehmkuhl G. Effectiveness of atomoxetine and quality of life in children with attention-deficit/hyperactivity disorder as perceived by patients, parents, and physicians in an open-label study. J Child Adolesc Psychopharmacol. 2007;17:813–830. doi: 10.1089/cap.2007.0025.
    1. Yang P, Hsu HY, Chiou SS, Chao MC. Health-related quality of life in methylphenidate-treated children with attention-deficit-hyperactivity disorder: Results from a Taiwanese sample. Aust N Z J Psychiatry. 2007;41:998–1004. doi: 10.1080/00048670701689451.
    1. Prasad S, Harpin V, Poole L, Zeitlin H, Jamdar S, Puvanendran K. A multi-centre, randomized, open-label study of atomoxetine compared with standard current therapy in UK children and adolescents with attention-deficit/hyperactivity disorder (ADHD) Curr Med Res Opin. 2007;23:379–394. doi: 10.1185/030079906X167309.
    1. Perwien AR, Kratochvil CJ, Faries DE, Vaughan BS, Spencer T, Brown RT. Atomoxetine treatment in children and adolescents with attention-deficit hyperactivity disorder: What are the long-term health-related quality-of-life outcomes? J Child Adolesc Psychopharmacol. 2006;16:713–724. doi: 10.1089/cap.2006.16.713.
    1. Brown RT, Perwien A, Faries DE, Kratochvil CJ, Vaughan BS. Atomoxetine in the management of children with ADHD: Effects on quality of life and school functioning. Clin Pediatr. 2006;45:819–827. doi: 10.1177/0009922806294219.
    1. Matza LS, Rentz AM, Secnik K, Swensen AR, Revicki DA, Michelson D, Spencer T, Newcorn JN, Kratochvil CJ. The link between health-related quality of life and clinical symptoms among children with attention-deficit hyperactivity disorder. J Dev Behav Pediatr. 2004;25:166–174. doi: 10.1097/00004703-200406000-00005.
    1. Newcorn JH, Spencer TJ, Biederman J, Milton DR, Michelson D. Atomoxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder. J Am Acad Child Adolesc Psychiatry. 2005;44:240–248. doi: 10.1097/00004583-200503000-00008.
    1. Rugino T, Arnold LE, Reinhard S. Efficacy of transdermal methylphenidate in subjects converted from oral methylphenidate. Poster presented at American Academy of Child and Adolescent Psychiatry Congress. San Diego, CA: 2006 Oct 27.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa